Microbiological and clinical characteristics of Streptococcus pneumoniae serotype 3 infection and risk factors for severe outcome: A multicenter observational study-Reference-Cited by-同舟云学术

Microbiological and clinical characteristics of Streptococcus pneumoniae serotype 3 infection and risk factors for severe outcome: A multicenter observational study

Published:2023-06 Issue:3 Volume:56 Page:598-604
ISSN:1684-1182
Container-title:Journal of Microbiology, Immunology and Infection
language:en
Short-container-title:Journal of Microbiology, Immunology and Infection

Author:

Aydin Merve Arslan^ORCID,Janapatla Rajendra Prasad^ORCID,Chen Chyi-Liang^ORCID,Li Hsin-Chieh,Su Lin-Hui,Chiu Cheng-Hsun^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,General Medicine,Immunology and Allergy

Reference24 articles.

1. JMM Profile: Streptococcus pneumoniae: sugar-coated captain of the men of death;Dao;J Med Microbiol,2021

2. Sugar-coated killer: serotype 3 pneumococcal disease;Luck;Front Cell Infect Microbiol,2020

3. Evolution of Streptococcus pneumoniae serotype 3 in England and Wales: a major vaccine evader;Groves;Genes (Basel),2019

4. National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017–2020

5. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes;van Hoek;PLoS One,2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study;The Lancet Infectious Diseases;2024-05

2. Diabetes as a risk factor for pneumococcal disease and severe related outcomes and efficacy/effectiveness of vaccination in diabetic population. Results from meta-analysis of observational studies;Acta Diabetologica;2024-04-29

3. Global trends in non-susceptibility rates of Streptococcus pneumoniae isolates to ceftriaxone: Data from the antimicrobial testing leadership and surveillance (ATLAS) programme, 2016–21;International Journal of Antimicrobial Agents;2024-02

4. Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021;Frontiers in Public Health;2023-05-30